CN117731707A - Broccoli composition with brain fog improving effect, and preparation method and application thereof - Google Patents
Broccoli composition with brain fog improving effect, and preparation method and application thereof Download PDFInfo
- Publication number
- CN117731707A CN117731707A CN202311775669.3A CN202311775669A CN117731707A CN 117731707 A CN117731707 A CN 117731707A CN 202311775669 A CN202311775669 A CN 202311775669A CN 117731707 A CN117731707 A CN 117731707A
- Authority
- CN
- China
- Prior art keywords
- broccoli
- weight
- sugar alcohol
- parts
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 title claims abstract description 81
- 235000017647 Brassica oleracea var italica Nutrition 0.000 title claims abstract description 81
- 210000004556 brain Anatomy 0.000 title claims abstract description 68
- 230000000694 effects Effects 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 244000308180 Brassica oleracea var. italica Species 0.000 title description 3
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims abstract description 78
- -1 phospholipid compound Chemical class 0.000 claims abstract description 48
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000000284 extract Substances 0.000 claims abstract description 30
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 27
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 27
- 239000003595 mist Substances 0.000 claims description 15
- 239000006286 aqueous extract Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 11
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 4
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 4
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 3
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 239000002994 raw material Substances 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 17
- 229960004373 acetylcholine Drugs 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 10
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 10
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 10
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000015654 memory Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000001694 spray drying Methods 0.000 description 8
- RUQCCAGSFPUGSZ-OBWQKADXSA-N Glucoraphanin Natural products C[S@](=O)CCCCC(=NS(=O)(=O)O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RUQCCAGSFPUGSZ-OBWQKADXSA-N 0.000 description 7
- GMMLNKINDDUDCF-JRWRFYLSSA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1e)-5-[(r)-methylsulfinyl]-n-sulfooxypentanimidothioate Chemical compound C[S@@](=O)CCCC\C(=N/OS(O)(=O)=O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMMLNKINDDUDCF-JRWRFYLSSA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 102000012440 Acetylcholinesterase Human genes 0.000 description 5
- 108010022752 Acetylcholinesterase Proteins 0.000 description 5
- 229940022698 acetylcholinesterase Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000019771 cognition Effects 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 4
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 4
- 101150054987 ChAT gene Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 101100203187 Mus musculus Sh2d3c gene Proteins 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000001652 frontal lobe Anatomy 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960005559 sulforaphane Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 230000003936 working memory Effects 0.000 description 3
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000010217 densitometric analysis Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000015487 sulforaphane Nutrition 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100425744 Mus musculus Ngfr gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000007623 cholinergic neuronal function Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007328 extracellular aggregation Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000007149 gut brain axis pathway Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 230000007334 memory performance Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000007511 neuronal proliferation Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000001366 vegetable intake Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a broccoli composition with a brain fog improving effect, and a preparation method and application thereof. The adhesive comprises the following components in parts by weight: 10 to 45 weight parts of broccoli seed water extract, 5 to 35 weight parts of phospholipid compound and 2 to 10 weight parts of sugar alcohol. Compared with the prior art, the compound has scientific and reasonable formula, adopts common medicinal and edible raw materials and health food raw materials, and is proved by a large number of experiments to be capable of well improving brain fog, safe and effective and free of other toxic and side effects.
Description
Technical Field
The invention relates to a composition, in particular to a broccoli composition with a brain fog improving effect, and a preparation method and application thereof.
Background
In recent years, brain mist has attracted more and more attention. The symptoms of white lung, encephalitis, cerebrovascular accident and the like can occur in the patient infected by the COVID-19, and the common symptom is left cognitive disorder. Furthermore, continuous chemotherapy and aging of healthy people in patients with cancer can cause brain fog: processing speed, working memory, visual memory and linguistic memory are reduced. The population ratio of brain fog is not small.
The pathological mechanism of brain fog formation has not been clearly elucidated, and some studies suggest that brain fog and inflammatory factors in the brain and oxidation lead to abnormal nerve expression. It has been found that chemotherapy induces oxidative stress and apoptosis, inhibits neuronal proliferation and differentiation, activates microglial cells, affects chromatin remodeling, and leads to abnormal expression of neurotrophins in the brain of experimental animals. These molecular changes are associated with changes in nerves and learning and memory deficits. It has been found that chemotherapy exposure may accelerate brain aging, and the resulting brain fog is manifested on the hippocampus and frontal lobe precursors, which play a key role in memory, learning and executive function. Frontal precursors are related to "executive functions," such as decision making, planning and judgment, and working memory.
The existence of brain fog seriously affects the life and work of people, so that effective measures must be taken for improvement. In addition to maintaining a good lifestyle for daily fitness and early sleep, some other treatment methods, such as eating health or medication, may be used if necessary.
However, the compound which is compounded by health food raw materials, can improve brain fog, is safe and effective, and has no other toxic or side effect is lacking at present.
Disclosure of Invention
Based on the current situation that effective compound for improving brain fog is lacking in the prior art, the invention provides a broccoli composition with the effect of improving brain fog, and a preparation method and application thereof.
The aim of the invention can be achieved by the following technical scheme:
the invention provides a broccoli composition with a brain mist improving effect, which comprises the following components in parts by weight:
10-45 parts by weight of broccoli seed water extract;
5-35 parts by weight of phospholipid compound;
2-10 parts by weight of sugar alcohol.
In one embodiment of the present invention, the aqueous broccoli seed extract is preferably 15 to 40 parts by weight, and more preferably 25 to 35 parts by weight.
In one embodiment of the present invention, the phospholipid compound is preferably 10 to 30 parts by weight, and more preferably 15 to 20 parts by weight.
In one embodiment of the present invention, the sugar alcohol is preferably 4 to 9 parts by weight, and more preferably 5 to 7 parts by weight.
In one embodiment of the invention, the weight ratio of the broccoli seed water extract to the phospholipid compound is 0.2-9:1, wherein the weight ratio of the water extract of broccoli seeds to the sugar alcohol is 1-12.5:1, a step of; the weight ratio of the phospholipid compound to the sugar alcohol is 0.5-17.5:1.
in one embodiment of the present invention, the weight ratio of the broccoli seed aqueous extract to the phospholipid compound is preferably 0.5 to 4:1, wherein the weight ratio of the water extract of broccoli seeds to the sugar alcohol is 1.6-10:1, a step of; the weight ratio of the phospholipid compound to the sugar alcohol is 1.1-10:1.
in one embodiment of the present invention, the weight ratio of the broccoli seed aqueous extract to the phospholipid compound is preferably 1.25-2.3:1, wherein the weight ratio of the water extract of broccoli seeds and the sugar alcohol is 3.5-7:1, a step of; the weight ratio of the phospholipid compound to the sugar alcohol is 2.1-4:1.
in one embodiment of the present invention, the phospholipid compound comprises at least phosphatidylserine.
In one embodiment of the present invention, the phospholipid compound further comprises one or more of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, or phosphatidylglycerol.
In one embodiment of the invention, the sugar alcohol comprises at least galacto-oligosaccharides.
In one embodiment of the invention, the sugar alcohol further comprises one or a combination of several of xylo-oligosaccharide, xylitol, soy oligosaccharide, fructo-oligosaccharide, mannooligosaccharide, isomaltooligosaccharide or mannitol.
In one embodiment of the present invention, the aqueous extract of broccoli seeds is prepared from broccoli seeds by hot water extraction, solid-liquid separation, concentration, spray drying and other steps, and contains proteins, glucoraphanin and the like as main components. Furthermore, a plant extract comprising glucoraphanin may also be used as an aqueous broccoli seed extract.
The invention further provides a preparation method of the broccoli composition with the effect of improving brain fog, which comprises the steps of dissolving broccoli seed water extract, phospholipid compound and sugar alcohol with water, and then spray drying.
In one embodiment of the invention, the amount of water upon dissolution is from 1 to 10 times, preferably from 2 to 5 times, relative to the total weight of dry matter of the composition.
The composition of the present invention may be prepared by mixing and dissolving, for example, an aqueous extract of broccoli seeds and/or a first plant extract comprising glucoraphanin, a phospholipid compound and a sugar alcohol. The method and means for dissolving the above-described essential components and optional components are not limited. The composition according to the invention may be prepared by mixing the essential and optional ingredients described above using any conventional methods and means.
In one embodiment of the present invention, the composition may be in powder form, but is not limited to powder form, and when dissolved, water in different proportions is added to form a liquid form, or the composition may not be dissolved with water, and the composition may be directly mixed with dry powder, or may be added to various capsules or preparations.
The invention further provides application of the broccoli composition with the effect of improving the brain fog, and the broccoli composition with the effect of improving the brain fog is used for preparing medicines or health care products with the effect of improving the brain fog.
Broccoli is a cruciferous plant, the seed of which is rich in thioglucoside. The broccoli seed is used as raw material, and the product is prepared through hot water extraction, solid-liquid separation, concentration, spray drying and other steps, and contains protein, glucoraphanin, etc. The glucoraphanin is a precursor of sulforaphane-sulforaphane, has higher stability compared with sulforaphane, and can be converted into sulforaphane in human body. The glucoraphanin in broccoli seeds can be converted into glucoraphanin (SFN) with antioxidant, antiinflammatory and anticancer effects. Furthermore, cruciferous vegetable intake is positively correlated with memory performance, processing speed and overall cognitive function in healthy elderly people. Animal studies have reported that SFN intake can improve working memory performance. In human studies, one patient study showed that ingestion of SFN improved cognitive performance, including memory. Therefore, the broccoli seed water extract has a plurality of effects in human bodies, and can prevent and treat skin cancer, breast cancer, colon cancer, inflammation, antioxidation and the like which are caused by intestinal tracts. The anti-inflammatory and antioxidant effects are important in improving brain fog.
The phospholipid compounds include, but are not limited to, phosphatidylserine (PS), phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylglycerol. Among them, phosphatidylserine (PS) is also called serine phospholipid, diacylglycerol Phosphatidylserine (PS) for short, is a ubiquitous phospholipid, is usually located in the inner layer of cell membrane, and phosphoglycerides in the phosphoester compound are one of cell membrane components and are related to a series of membrane functions. It can help the cell wall to maintain flexibility and enhance the efficiency of neurotransmitters transmitting brain signals, help the brain to operate with high efficiency, and excite the brain's activated state. At the earliest, phosphatidylserine was used for preventing senile dementia, and in recent years, the application subjects of phosphatidylserine are gradually younger as the clinical experiments of memory progress. It can also safely enhance the memory in a short period, supplement phosphatidylserine, increase the number of cerebral spurs, the mobility of cerebral cell membranes and promote glucose metabolism in cerebral cells, thereby enabling the cerebral cells to be more active, promoting concentration of attention, and improving alertness and memory; phosphatidylserine (PS) also helps to relieve brain fatigue and repair brain cell damage. Because of this particular function, phosphatidylserine-related nutritional supplements are used in a number of applications for pre-examination nutritional supplements. Phosphatidylserine is important for maintaining the normal function of nerve cells, and is the only component of phospholipid which can control the cell membrane function related protein. Exogenous PS can improve central nervous functions including cognition, it can activate key signaling pathways, promote neuronal development and neurogenic differentiation. Phosphatidylcholine reduces lipopolysaccharide-induced synaptic dysfunction and nerve damage by modulating synaptic proteins and neurotrophic factors and expression. The mechanism may be to prevent the occurrence of inflammatory reactions through the gut-brain axis.
The polyhydric structure of galacto-oligosaccharide gives it the ability to bind water and therefore it has the effects of maintaining food moisture, improving or maintaining softness, improving rehydration of dehydrated food, controlling crystallization and even controlling viscosity and texture of food, reducing water activity etc.
The invention provides a compound with brain fog improving effect, which is prepared by compounding raw materials with homology of medicine and food of broccoli seed water extract and a phospholipid compound at least containing phosphatidylserine.
Compared with the prior art, the compound has scientific and reasonable formula, adopts common medicinal and edible raw materials and health food raw materials, and is proved by a large number of experiments to be capable of well improving brain fog, safe and effective and free of other toxic and side effects.
Drawings
The effect of the complex of FIG. 1 on the ACh and AChe activity in mice;
FIG. 2 densitometric analysis results of hippocampal (left)/frontal (right) ChAT mRNA levels using RT-PCR gel and Western Blot;
FIG. 3 densitometric analysis of p75NTR relative to beta-Actin protein expression levels using RT-PCR gel and Western Blot.
Detailed Description
The present invention will be described in further detail with reference to specific embodiments in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
Example 1: the broccoli compound with the effect of improving brain fog comprises the following raw materials in parts by weight:
1. 40 parts of broccoli seed water extract, 15 parts of phosphatidylserine and 5 parts of sugar alcohol;
2. the preparation method comprises the following steps:
(1) Dissolving 40 parts of broccoli seed water extract, 15 parts of phosphatidylserine and 5 parts of galacto-oligosaccharide in 120 parts of water;
(2) Spray drying the solution in the step (1);
example 2: the broccoli compound with the effect of improving brain fog comprises the following raw materials in parts by weight:
1. 30 parts of broccoli seed water extract, 25 parts of phosphatidylserine and 7 parts of sugar alcohol;
2. the preparation method comprises the following steps:
(1) Weighing 20 parts of broccoli seed water extract, 25 parts of phosphatidylserine and 7 parts of galacto-oligosaccharide, and uniformly mixing;
(2) Mixing the raw materials in the step (1) for 5min by a traditional Chinese medicine powder grinding machine, and cooling for standby;
example 3: protection of mouse brain fog by the complex
1. The experimental method comprises the following steps: 30 Kunming mice are randomly divided into 3 groups after being adaptively fed for 1 week, 10 mice in each group are respectively a blank control group, a model group and an experimental group, scopolamine hydrobromide 2.0mg/kg.bw is injected into the abdominal cavity of the mice in each experimental group except the blank group, and physiological saline with the same amount as scopolamine hydrobromide is infused into the mice in the blank group; after 1h, the blank and model groups were filled with 6mL/kg. Bw of physiological saline and the other experimental groups were filled with 6mL/kg. Bw of CMC-Na solution of the compound obtained in example 1 (compound content: 20%) so that the total was filled with stomach for 30 days each 1 time in the morning and evening.
2. Effects on mouse hippocampal and frontal cortex acetylcholine (ACh) and acetylcholine transferase (ChAT) expression
The neurotransmitter acetylcholine (ACh) is essential for central and peripheral control of a variety of cognitive processes including time, attention, learning and memory. Thus, cholinergic neuronal damage reduces acetylcholine release into the synaptic cleft, resulting in learning and memory dysfunction. Acetylcholine released from nerves is hydrolyzed by acetylcholinesterase (AChe), and the higher the activity of acetylcholinesterase, the longer the duration of action, inhibition of acetylcholinesterase is a therapeutic approach to treat alzheimer's disease, other types of dementia, traumatic brain injury, and delirium.
The data are based on a blank control group, and as can be clearly seen in fig. 1, compared with the blank group, the content of acetylcholine in the hippocampus and frontal lobe precursors of a model group of mice is obviously reduced, and the compound in the experimental group is obviously helpful for increasing acetylcholine in the mice, so that the compound has better effect of increasing cognition.
3. Effect on mouse acetylcholine transferase (ChAT) expression
Acetylcholine is synthesized by the enzyme acetylcholine transferase (choline acetyltransferase, chAT), the most specific marker of cholinergic neuronal function in the central and peripheral nervous systems. In the elderly brain, chAT activity is significantly reduced, and the extent of reduced activity is significantly correlated with the severity of cognitive impairment.
Beta-action is a common reference for PCR, and beta-action antibodies are excellent reference indexes of Western Blot. Internal reference is an Internal reference (Internal Control) and for mammalian cell expression refers generally to the protein encoded and expressed by the housekeeping gene. Their expression in various tissues and cells is relatively constant and is commonly used as a reference when detecting changes in the level of protein expression.
As is evident from fig. 2, there was no significant difference in ChAT values in the model group, but a significant increase in ChAT values in the experimental group, relative to the blank group, in the hippocampal region. In frontal lobe region, chAT values were significantly reduced in model group versus blank group, and ChAT values were significantly increased in experimental group. The combination shows that scopolamine hydrobromide can cause the decrease of the ChAT value in mice, and the increase of the ChAT value in mice after the injection of the compound shows that the compound has better effect of improving cognition, namely brain fog.
4. Effect on mouse p75NTR Gene expression
The extracellular aggregation of the β -amyloid (a- β) polypeptide leads to plaque formation and intracellular hyperphosphorylated tau accumulation, which in turn leads to the formation of neurofibrillary tangles and ultimately also to the development of cognitive disorders. Deletion of the p75NTR gene contributes to the increase in A-. Beta.aggregates. Thus, up-regulation of p75NTR is an effective therapeutic strategy to reduce a- β aggregate formation in the brain.
As can be seen from fig. 3, the p75NTR gene expression in the model group was significantly reduced in the cerebral cortex relative to the blank group, and the p75NTR gene expression in the experimental group was not increased but the difference from the p75NTR gene expression in the blank group was small. The p75NTR gene expression of the experimental group is obviously increased compared with that of the p75NTR gene expression of the model group. This demonstrates that scopolamine hydrobromide causes reduced p75NTR gene expression in mice, whereas the p75NTR gene expression in mice injected with the complex increases, reduces the formation of a-beta aggregates in the brain, improves cognitive impairment, and has less phase difference than normal mice, and can be used to improve brain fog symptoms.
Example 4
The embodiment provides a broccoli composition with brain mist improving effect, which comprises the following components in parts by weight:
10 parts of broccoli seed water extract;
5 parts by weight of a phospholipid compound;
sugar alcohol 2 parts by weight.
In this embodiment, the phospholipid compound is phosphatidylserine and phosphatidylcholine with a mass ratio of 1:1.
In the embodiment, the sugar alcohol is a mixture of galactooligosaccharide, xylooligosaccharide and xylitol in a mass ratio of 1:1:1.
The preparation method comprises the following steps: dissolving broccoli seed water extract, phospholipid compound and sugar alcohol with water, and spray drying. The amount of water was 5 times relative to the total weight of dry matter of the composition.
The broccoli composition with the effect of improving brain fog is used for preparing medicines or health care products with the effect of improving brain fog.
Example 5
The embodiment provides a broccoli composition with brain mist improving effect, which comprises the following components in parts by weight:
45 parts by weight of an aqueous broccoli seed extract;
35 parts of phospholipid compound;
10 parts by weight of sugar alcohol.
In this embodiment, the phospholipid compound is phosphatidylserine and phosphatidylethanolamine with a mass ratio of 1:1.
In this embodiment, the sugar alcohol is a mixture of galacto-oligosaccharide, soy oligosaccharide and fructo-oligosaccharide in a mass ratio of 1:1:1.
The preparation method comprises the following steps: mixing the water extract of broccoli seed, phospholipid compound and sugar alcohol directly with dry powder.
The broccoli composition with the effect of improving brain fog is used for preparing medicines or health care products with the effect of improving brain fog.
Example 6
The embodiment provides a broccoli composition with brain mist improving effect, which comprises the following components in parts by weight:
15 parts by weight of an aqueous extract of broccoli seeds;
10 parts by weight of a phospholipid compound;
sugar alcohol 4 parts by weight.
In this embodiment, the phospholipid compound is phosphatidylserine and phosphatidylglycerol with a mass ratio of 1:1.
In this example, the sugar alcohol is a mixture of galactooligosaccharide, mannooligosaccharide and isomaltooligosaccharide in a mass ratio of 1:1:1.
The preparation method comprises the following steps: adding water extract of broccoli seed, phospholipid compound and sugar alcohol into capsule or preparation.
The broccoli composition with the effect of improving brain fog is used for preparing medicines or health care products with the effect of improving brain fog.
Example 7
The embodiment provides a broccoli composition with brain mist improving effect, which comprises the following components in parts by weight:
40 parts by weight of an aqueous extract of broccoli seeds;
30 parts of phospholipid compound;
9 parts by weight of sugar alcohol.
In this embodiment, the phospholipid compound is phosphatidylserine and phosphatidylinositol with a mass ratio of 1:1.
In this embodiment, the sugar alcohol is a mixture of galactooligosaccharide, isomaltooligosaccharide and mannitol in a mass ratio of 1:1:1.
The preparation method comprises the following steps: dissolving broccoli seed water extract, phospholipid compound and sugar alcohol with water, and spray drying. The amount of water was 4 times relative to the total weight of dry matter of the composition.
The broccoli composition with the effect of improving brain fog is used for preparing medicines or health care products with the effect of improving brain fog.
Example 8
The embodiment provides a broccoli composition with brain mist improving effect, which comprises the following components in parts by weight:
25 parts by weight of an aqueous extract of broccoli seeds;
15 parts of phospholipid compound;
5 parts by weight of sugar alcohol.
In this embodiment, the phospholipid compound is phosphatidylserine and phosphatidylcholine with a mass ratio of 1:1.
In the embodiment, the sugar alcohol is a mixture of galactooligosaccharide, xylooligosaccharide and xylitol in a mass ratio of 1:1:1.
The preparation method comprises the following steps: dissolving broccoli seed water extract, phospholipid compound and sugar alcohol with water, and spray drying. The amount of water was 5 times relative to the total weight of dry matter of the composition.
The broccoli composition with the effect of improving brain fog is used for preparing medicines or health care products with the effect of improving brain fog.
Example 9
The embodiment provides a broccoli composition with brain mist improving effect, which comprises the following components in parts by weight:
35 parts by weight of broccoli seed water extract;
20 parts of phospholipid compound;
7 parts by weight of sugar alcohol.
In this embodiment, the phospholipid compound is phosphatidylserine and phosphatidylcholine with a mass ratio of 1:1.
In the embodiment, the sugar alcohol is a mixture of galactooligosaccharide, xylooligosaccharide and xylitol in a mass ratio of 1:1:1.
The preparation method comprises the following steps: dissolving broccoli seed water extract, phospholipid compound and sugar alcohol with water, and spray drying. The amount of water was 5 times relative to the total weight of dry matter of the composition.
The broccoli composition with the effect of improving brain fog is used for preparing medicines or health care products with the effect of improving brain fog.
The previous description of the embodiments is provided to facilitate a person of ordinary skill in the art in order to make and use the present invention. It will be apparent to those skilled in the art that various modifications can be readily made to these embodiments and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above-described embodiments, and those skilled in the art, based on the present disclosure, should make improvements and modifications without departing from the scope of the present invention.
Claims (10)
1. A broccoli composition with brain mist improving effect, which is characterized by comprising the following components in parts by weight:
10-45 parts by weight of broccoli seed water extract;
5-35 parts by weight of phospholipid compound;
2-10 parts by weight of sugar alcohol.
2. The broccoli composition having an effect of improving brain fog according to claim 1, wherein the aqueous extract of broccoli seeds is 15 to 40 parts by weight; 10 to 30 parts by weight of the phospholipid compound; the sugar alcohol is 4 to 9 parts by weight.
3. The broccoli composition having an effect of improving brain fog according to claim 2, wherein the aqueous extract of broccoli seeds is 25 to 35 parts by weight; 15 to 20 parts by weight of the phospholipid compound; the sugar alcohol is 5 to 7 parts by weight.
4. The broccoli composition with brain mist improving effect according to claim 1, wherein the weight ratio of the broccoli seed aqueous extract to the phospholipid compound is 0.2-9:1, wherein the weight ratio of the water extract of broccoli seeds to the sugar alcohol is 1-12.5:1, a step of; the weight ratio of the phospholipid compound to the sugar alcohol is 0.5-17.5:1.
5. the broccoli composition with brain mist improving effect according to claim 4, wherein the weight ratio of the broccoli seed aqueous extract to the phospholipid compound is 0.5-4:1, wherein the weight ratio of the water extract of broccoli seeds to the sugar alcohol is 1.6-10:1, a step of; the weight ratio of the phospholipid compound to the sugar alcohol is 1.1-10:1.
6. the broccoli composition with brain mist improving effect according to claim 5, wherein the weight ratio of the broccoli seed aqueous extract to the phospholipid compound is 1.25-2.3:1, wherein the weight ratio of the water extract of broccoli seeds to the sugar alcohol is 3.5-7:1, a step of; the weight ratio of the phospholipid compound to the sugar alcohol is 2.1-4:1.
7. the broccoli composition with brain mist improving effect according to claim 1, wherein the phospholipid compound comprises at least phosphatidylserine;
the phospholipid compound also comprises one or more of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol or phosphatidylglycerol.
8. A broccoli composition having an effect of improving brain mist according to claim 1, characterized in that the sugar alcohol contains at least galacto-oligosaccharides;
the sugar alcohol also comprises one or a combination of several of xylo-oligosaccharide, xylitol, soybean oligosaccharide, fructo-oligosaccharide, mannooligosaccharide, isomaltooligosaccharide or mannitol.
9. The method for preparing a broccoli composition with brain mist improving effect according to any one of claims 1 to 8, characterized in that the broccoli seed aqueous extract, the phospholipid compound, the sugar alcohol are dissolved with water and then spray-dried; or alternatively, the first and second heat exchangers may be,
mixing the water extract of broccoli seed, phospholipid compound and sugar alcohol directly with dry powder; or alternatively, the first and second heat exchangers may be,
adding water extract of broccoli seed, phospholipid compound and sugar alcohol into capsule or preparation.
10. Use of a broccoli composition with brain mist-improving effect according to any one of the claims 1 to 8, characterized in that the broccoli composition with brain mist-improving effect is used for the preparation of a medicament or a health product with brain mist-improving effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311775669.3A CN117731707A (en) | 2023-12-22 | 2023-12-22 | Broccoli composition with brain fog improving effect, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311775669.3A CN117731707A (en) | 2023-12-22 | 2023-12-22 | Broccoli composition with brain fog improving effect, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117731707A true CN117731707A (en) | 2024-03-22 |
Family
ID=90277358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311775669.3A Pending CN117731707A (en) | 2023-12-22 | 2023-12-22 | Broccoli composition with brain fog improving effect, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117731707A (en) |
-
2023
- 2023-12-22 CN CN202311775669.3A patent/CN117731707A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2946825C (en) | Muscle atrophy inhibitor containing quercetin glycoside | |
| EP2708147B1 (en) | Methods for increasing brain functionality using 2-fucosyl-lactose | |
| ES2431142T3 (en) | Fat accumulation inhibitor for the treatment of metabolic syndrome | |
| JP5498521B2 (en) | Radiation damage reducing agent | |
| JP5271534B2 (en) | Muscle atrophy inhibitor | |
| WO2001087291A1 (en) | Compositions normalizing circadian rhythm | |
| CN103608025B (en) | For preventing or treat the compositions comprising herb extracts of neurodegenerative diseases | |
| EP2859896B1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
| KR20100105598A (en) | Sense-improving agent | |
| WO2018164221A1 (en) | Composition for inhibiting myofibrosis | |
| JP4203159B2 (en) | Nerve function regulator | |
| US20130252923A1 (en) | Skin-beautifying agent | |
| KR20210064915A (en) | Composition for improving muscle function, comprising grub extract | |
| JP2011241209A (en) | Bdnf production accelerator having ganglioside or derivative thereof as active ingredient, and medical product, food and drink and feed containing the bdnf production accelerator | |
| CN117731707A (en) | Broccoli composition with brain fog improving effect, and preparation method and application thereof | |
| CN112716969B (en) | Composition for treating Alzheimer's disease as well as preparation method and application thereof | |
| US20240197665A1 (en) | Pharmaceutical Composition For Treating Hyperlipidemia And Preparation Method Therefor | |
| KR20140119236A (en) | Composition for anxiolitic, anti-convulsant, anti-depressant or sleep-improving effect comprising shellfish extract as an effective component | |
| KR101769972B1 (en) | A composition for improving, preventing and treating pulmonary disease comprising herb extract | |
| KR101041044B1 (en) | A composition for reducing sleep induction time and prolonging sleeping time, and a method for preparing the same | |
| KR101613252B1 (en) | Compositions for Preventing or Treating Obesity and Fatty Liver Containing Ariginase Inhibitors | |
| KR102533545B1 (en) | Pharmacological Composition for Treating or Preventing the Ischemia Stroke Disease Containing Alpinumisoflavone | |
| CN116492327B (en) | Application of (2S, 6S) -2, 6-diaminopimelic acid in preparation of anti-postpartum depression drugs | |
| US8128969B2 (en) | Hypoglycemic composition containing acacia bark derivative | |
| KR20230087245A (en) | Pharmacological Composition for Treating or Preventing the ischemia Stroke Disease Containing active ingredient for alkaloid of sessiline extract Acanthopanaxs sessiliflours |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |